SOLX Establishes International Certification Program.

Glaucoma Specialists Receive Clinical Training and Surgical Support

BOSTON -- SOLX([R]), the glaucoma division of OccuLogix([R]), Inc., announced the initiation of its international training and certification program. Ophthalmologists in Europe and the Middle East can now become certified to perform surgical implantation procedures using SOLX Gold Micro-Shunt products (GMS) to treat glaucoma patients.

An educational symposium was held this morning at the Venetian Hotel in Las Vegas prior to the commencement of the 110th American Academy of Ophthalmology (AAO) annual meeting. Ike Ahmed, MD and Shlomo Melamed, MD, and Modi Goldenfeld, MD led this morning's program which included presentations in uveoscleral anatomy and physiology as well as video demonstrations of GMS implantation techniques.

Additional didactic training sessions are being offered internationally at various locations and can be located at www.solx.com. Surgical certification, which includes implantation of the GMS, is performed at the surgeon's own practice.

"We believe that SOLX Gold Micro-Shunt products offer a significant advancement in the treatment of glaucoma by eliminating blebs and bleb-related complications," said Doug Adams, President of the OccuLogix glaucoma division. "Our goal is that every ophthalmologist has the opportunity to receive comprehensive GMS training to achieve successful outcomes and improve the quality of life for their glaucoma patients."

The GMS was launched at the European Society of Cataract and Refractive Surgeons (ESCRS) meeting in London this past September. US FDA clinical studies are currently underway at ten centers worldwide.

GMS products are 24-karat gold biocompatible ultra-thin implants that are approximately half the thickness of a human hair. Unlike tubular drainage devices, GMS are flat plates containing numerous micro-tubular channels that create a bridge between the anterior chamber and suprachoroidal space. They use the eye's natural pressure differential to maximize uveoscleral outflow and reduce IOP without a bleb. The devices are implanted through a single, 4mm micro-incision and rest permanently in the suprachoroidal space.

SOLX can be visited at booth number 5021 at the Sands Expo/Venetian in Las Vegas from November 11 - 13 during the AAO annual meeting. More information on SOLX products and training is available at www.solx.com.

ABOUT SOLX

SOLX is based at the Boston University Photonics Center in Boston, Massachusetts. In September 2006, SOLX was acquired by OccuLogix, Inc. (NASDAQ:OCCX)(TSX:OC). Now operating as the glaucoma division of OccuLogix, SOLX is developing new tools to reduce intraocular pressure in glaucoma patients with the SOLX Gold Micro Shunt (GMS) and the SOLX 790 Titanium Sapphire Laser. More information can be found online at www.solx.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the Company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.